July 19, 2026

The Economics of Home OCT

At ASRS 2026, Sean Berkowitz, MD, MBA, examined the payer costs and physician workload associated with home OCT monitoring for wet AMD.

July 19, 2026

ASRS President Reflects on a Year of Change

As his term comes to a close, Geoffrey G. Emerson, MD, PhD, FASRS, discusses scientific advances, physician advocacy, and the collaborative leadership behind ASRS.

July 19, 2026

Lessons From the ARCHER Trial

Margaret A. Chang, MD, MS, discusses how findings from the phase 2 ARCHER trial informed the design of the ongoing phase 3 ARCHER II study of vonaprument, which is expected to read out later this year.

July 19, 2026

Merck Highlights Early Tiespectus Data

At the ASRS meeting in Montreal, Baruch D. Kuppermann, MD, PhD, presented BRVO findings from the phase 1/2a RIOJA program evaluating the investigational VEGF/Tie2 bispecific.

July 19, 2026

Does Timing Matter in Gene Therapy for nAMD?

Carl C. Awh, MD, FASRS, discusses 2-year phase 2b PRISM results showing durable outcomes with investigational 4D-150 in patients with recently diagnosed neovascular age-related macular degeneration.

July 19, 2026

A First Look at Phase 2 ArMaDa Data

Arshad M. Khanani, MD, FASRS, discusses phase 2 findings for OCU410, an investigational gene therapy for geographic atrophy. A phase 3 program is expected to begin later this year.

July 17, 2026

Stuart Therapeutics Spotlights Topical RP Program

At OIS Retina, Eric Schlumpf discussed the company’s collagen mimetic peptide platform for retinitis pigmentosa, now in preclinical development.

July 17, 2026

Alkeus Launches Phase 3 Stargardt Trial

At OIS Retina, Carlos Quezada Ruiz, MD, highlighted the launch of the global phase 3 NORTHSTAR trial evaluating oral gildeuretinol for Stargardt disease.

July 17, 2026

Neuroprotection: Retina's Next Frontier?

At OIS Retina in Montreal, Riad Sherif, MD, discussed Oculis’s optic neuritis program and why neuroprotection may represent the next frontier in retinal therapeutics.

July 16, 2026

CMS Proposal Would Cut Payment for Same-Day Injection Visits

The proposed Physician Fee Schedule for 2027 includes changes affecting intravitreal injections, E/M services, and physician payment.